Get the Stockscreener App
30.80
4.90%
1.395
Alkermes Plc stock is traded at $30.80, with a volume of 811.06K.
It is up +4.90% in the last 24 hours and up +16.16% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$29.40
Open:
$29.86
24h Volume:
811.06K
Relative Volume:
0.48
Market Cap:
$5.09B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
15.79
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
+5.44%
1M Performance:
+16.16%
6M Performance:
-9.59%
1Y Performance:
+9.67%
1-Day Range:
$29.66
$31.69
1-Week Range:
$28.77
$31.69
52-Week Range:
$25.56
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
30.81 | 4.78B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
152.35 | 69.31B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.18 | 47.34B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.845 | 43.88B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.67 | 21.08B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
397.30 | 13.78B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Wells Fargo Initiates Alkermes Public at Overweight With $44 Price Target - MarketScreener
Applying sector rotation models to Alkermes plcNew Guidance & Free Safe Entry Trade Signal Reports - Newser
How to use a screener to detect Alkermes plc breakouts2025 Top Gainers & Verified Momentum Stock Alerts - Newser
Real time alert setup for Alkermes plc performanceWeekly Trade Analysis & Fast Moving Stock Trade Plans - Newser
When is the best time to exit Alkermes plc2025 Market Outlook & Expert Curated Trade Setups - Newser
What machine learning models say about Alkermes plcEarnings Risk Summary & Daily Technical Forecast Reports - Newser
Identifying reversal signals in Alkermes plcMarket Growth Review & Free Technical Pattern Based Buy Signals - Newser
Can swing trading help recover from Alkermes plc lossesPortfolio Growth Summary & High Accuracy Trade Alerts - Newser
Using Bollinger Bands to evaluate Alkermes plcTrade Volume Report & AI Driven Stock Reports - Newser
Does Alkermes plc show high probability of reboundWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
Analyzing recovery setups for Alkermes plc investorsWeekly Stock Summary & Daily Stock Trend Reports - Newser
How to track smart money flows in Alkermes plcJuly 2025 Market Mood & Weekly Setup with High ROI Potential - Newser
Does Alkermes plc qualify in momentum factor screening2025 Support & Resistance & Weekly Momentum Picks - Newser
Does Alkermes plc fit your quant trading modelQuarterly Earnings Summary & Low Risk Entry Point Guides - Newser
Alkermes plc (ALKS) Completes Enrollment in Key Narcolepsy Trial, Data Due Q3 2025 - Yahoo Finance
Visual trend scoring systems applied to Alkermes plcJuly 2025 Outlook & Reliable Intraday Trade Plans - Newser
Will a bounce in Alkermes plc offer an exitForecast Cut & Daily Technical Forecast Reports - Newser
How to integrate Alkermes plc into portfolio analysis toolsMarket Activity Report & Fast Moving Stock Watchlists - Newser
How to manage a losing position in Alkermes plcWeekly Volume Report & Risk Managed Investment Strategies - Newser
Can Alkermes plc maintain sales growthWeekly Investment Recap & Reliable Breakout Stock Forecasts - khodrobank.com
Is Alkermes plc a top pick in the sectorCEO Change & Smart Money Movement Tracker - khodrobank.com
How Alkermes plc stock performs during market volatilityWeekly Trade Analysis & Accurate Technical Buy Alerts - Newser
Is Alkermes plc stock undervalued right now2025 Pullback Review & Fast Entry Momentum Alerts - khodrobank.com
Alkermes plc stock trend outlook and recovery pathEarnings Performance Report & Safe Capital Growth Trade Ideas - Newser
Sentiment analysis tools applied to Alkermes plcJuly 2025 WrapUp & Real-Time Market Sentiment Reports - Newser
How to read the order book for Alkermes plcShare Buyback & Fast Gain Stock Tips - Newser
Alkermes plc stock trend forecastExit Point & Weekly Watchlist of Top Performers - Newser
Will Alkermes plc benefit from macro trends2025 Macro Impact & AI Forecasted Stock Moves - Newser
Will Alkermes plc outperform the marketMarket Sentiment Summary & Consistent Growth Equity Picks - Newser
Visual analytics tools that track Alkermes plc performance2025 Stock Rankings & Long-Term Safe Investment Plans - Newser
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.20%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):